← 返回专利悬崖列表
cRGD-ZW800-1
Tier C · 观察 / 贸易cRGD-ZW800-1
Curadel
原研
-
首批上市
-
到期年(公开口径)
无销量数据
峰值销售
化学药
类型
靶点:Not applicable
适应症(已批准):头颈部鳞状细胞癌、胆管上皮癌、胰腺癌
各地区研发/上市状态
美国
-
欧盟
临床二期
2022-11-09
中国
-
日本
-
合成路线与中间体4 routes
原研路线 × 0优化路线(非专利)× 4工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线(非专利)」排序。每条路线附本站自绘的路线流程图(中间体 → 原料药)与中间体表(编号 / CAS / 英文名),可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染,未使用任何第三方路线图。
优化Route 1步骤 4 · 总收率 /
(I)819152-1-a98-71-5(II)819152-1-a563-80-4(IIIa)819152-1-a184351-56-2(IIIb)819152-1-a132557-72-3(IV)819152-1-a3779-42-8(V)819152-1-a—(VI)819152-1-a108-94-1(VII)819152-1-a—(VIII)819152-1-a—(IX)819152-1-a—(X)819152-1-a501-97-3(XI)819152-1-a,(XI)819152-1-b2412139-24-1API · cRGD-ZW800-1
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| (I)819152-1-a | 98-71-5 | 4-Hydrazinobenzenesulfonic acid |
| (II)819152-1-a | 563-80-4 | 2-Acetylpropane |
| (IIIa)819152-1-a | 184351-56-2 | Potassium 2,3,3-trimethyl-3H-indole-5-sulfonate |
| (IIIb)819152-1-a | 132557-72-3 | 2,3,3-Trimethyl-3H-indole-5-sulfonic acid |
| (IV)819152-1-a | 3779-42-8 | 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide |
| (V)819152-1-a | - | 2,3,3-Trimethyl-5-sulfo-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium dibromide |
| (VI)819152-1-a | 108-94-1 | 4-Cyclohexanone |
| (VII)819152-1-a | - | [3-(Anilinomethylidene)-2-chlorocyclohex-1-en-1-yl]-N-phenylmethaniminium chloride |
| (VIII)819152-1-a | - | 2-[2-[2-Chloro-3-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]cyclohex-1-en-1-yl]ethenyl]-3,3-dimethyl-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-5-sulfonate sodium bromide (1/2/3) |
| (IX)819152-1-a | - | Disodium 3-(4-oxidophenyl)propanoate |
| (X)819152-1-a | 501-97-3 | 3-(4-Hydroxyphenyl)propionic acid |
| (XI)819152-1-a,(XI)819152-1-b | 2412139-24-1 | 3-[4-[[6-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-2-yl]ethenyl]cyclohex-1-en-1-yl]oxy]phenyl]propanoate trifluoroacetic acid |
优化Route 2步骤 2 · 总收率 /
(IIIb)819152-1-a132557-72-3(XI)819152-1-a,(XI)819152-1-b2412139-24-1(XII)819152-1-b—(XIII)819152-1-b,(XIII)819152-1-d217099-14-4API · cRGD-ZW800-1
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| (IIIb)819152-1-a | 132557-72-3 | 2,3,3-Trimethyl-3H-indole-5-sulfonic acid |
| (XI)819152-1-a,(XI)819152-1-b | 2412139-24-1 | 3-[4-[[6-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-[2-[3,3-dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-2-yl]ethenyl]cyclohex-1-en-1-yl]oxy]phenyl]propanoate trifluoroacetic acid |
| (XII)819152-1-b | - | 2-[2-[3-[2-[3,3-Dimethyl-5-sulfonato-1-[3-(trimethylazaniumyl)propyl]-1,3-dihydro-2H-indol-2-ylidene]ethylidene]-2-(4-[3-[(2,5-dioxopyrrolidin-1-yl)oxy]-3-oxopropyl]phenoxy)cyclohex-1-en-1-yl]ethenyl]-3,3-dimethyl-1-[3-(trimethylazaniumyl)propyl]-3H-indol-1-ium-5-sulfonate sodium bromide (1/2/2) |
| (XIII)819152-1-b,(XIII)819152-1-d | 217099-14-4 | Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-tyrosyl-L-lysyl) |
优化Route 3步骤 5 · 总收率 /
(XIV)819152-1-c—(XIX)819152-1-c—(XV)819152-1-c—(XVI)819152-1-c154445-77-9(XVII)819152-1-c—(XVIII)819152-1-c71989-26-9(XX)819152-1-c118488-18-9(XXI)819152-1-c—(XXII)819152-1-c71989-14-5(XXIII)819152-1-c,(XXIII)819152-1-d—API · cRGD-ZW800-1
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| (XIV)819152-1-c | - | Resin bound [([[(9H-Fluoren-9-yl)methoxy]carbonyl]amino)acetyl]oxy |
| (XIX)819152-1-c | - | Resin bound N-[(2S)-2-[[N6-(tert-butoxycarbonyl)-L-lysyl]oxy]-5-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentanoyl]glycine |
| (XV)819152-1-c | - | Resin bound glycine |
| (XVI)819152-1-c | 154445-77-9 | (2S)-2-{[(9H-Fluoren-9-ylmethoxy)carbonyl]amino}-5-[2-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentanoic acid |
| (XVII)819152-1-c | - | Resin bound N5-[N-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidoyl]-L-ornithylglycine |
| (XVIII)819152-1-c | 71989-26-9 | (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid |
| (XX)819152-1-c | 118488-18-9 | Fmoc-O-tert-butyl-D-tyrosine |
| (XXI)819152-1-c | - | Resin bound (2S)-1-[(carboxymethyl)amino]-1-oxo-5-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]pentan-2-yl O-tert-butyl-D-tyrosyl-N6-(tert-butoxycarbonyl)-L-lysinate |
| (XXII)819152-1-c | 71989-14-5 | (2S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid |
| (XXIII)819152-1-c,(XXIII)819152-1-d | - | Resin bound (5S,8S,11R,14S)-14-amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
优化Route 4步骤 3 · 总收率 /
(XIII)819152-1-b,(XIII)819152-1-d217099-14-4(XXIII)819152-1-c,(XXIII)819152-1-d—(XXIV)819152-1-d—(XXV)819152-1-d—API · cRGD-ZW800-1
| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| (XIII)819152-1-b,(XIII)819152-1-d | 217099-14-4 | Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-tyrosyl-L-lysyl) |
| (XXIII)819152-1-c,(XXIII)819152-1-d | - | Resin bound (5S,8S,11R,14S)-14-amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
| (XXIV)819152-1-d | - | (5S,8S,11R,14S)-14-Amino-8-[4-[(tert-butoxycarbonyl)amino]butyl]-11-[(4-tert-butoxyphenyl)methyl]-18,18-dimethyl-4,7,10,13,16-pentaoxo-5-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-6,17-dioxa-3,9,12-triazanonadecan-1-oic acid |
| (XXV)819152-1-d | - | tert-Butyl [(2S,5R,8S,11S)-8-[4-[(tert-butoxycarbonyl)amino]butyl]-5-[(4-tert-butoxyphenyl)methyl]-3,6,9,12,15-pentaoxo-11-[3-[N'-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-sulfonyl)carbamimidamido]propyl]-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetate |
常见问题(FAQ)
cRGD-ZW800-1的适应症有哪些?
已批准的适应症包括:头颈部鳞状细胞癌、胆管上皮癌、胰腺癌。
cRGD-ZW800-1的专利什么时候到期?
cRGD-ZW800-1的专利到期年暂无公开口径,本页会在数据管道核实后更新。
cRGD-ZW800-1有几条合成路线?
本站收录 4 条合成路线,最短路线 2 步、总收率 /。每条路线的中间体均带登记编号与 CAS 号。
cRGD-ZW800-1的关键中间体在哪里可以采购?
cRGD-ZW800-1路线中的中间体均已建立 CAS 档案,可直接按 CAS 发起询价,需求会进入供应网络撮合池。
如何获取cRGD-ZW800-1中间体的报价?
在本页选择目标中间体的 CAS 进入档案页,或在询价页直接提交需求;CAS 会自动带入供需撮合流程,由供应网络反馈报价。
数据来源:多源数据交叉核实(仅结构化字段) · 2026-10-03